| Name | Title | Contact Details |
|---|
Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.
tank consultants mech svcs inc is a Tulsa, OK-based company in the Business Services sector.
Scarborough Research is one of the leading providers in Business Services. It is based in New York, NY. To find more information about Scarborough Research, please visit www.scarborough.com.
Bobroff, Hesse, Lindmark is a Saint Louis, MO-based company in the Business Services sector.
Smeltzer Orchard Co Whol is a Frankfort, MI-based company in the Business Services sector.